SCHEMBL416772

SCHEMBL416772

CC=CC=C/C=C/C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
TP53 P04637 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
EGLN3 Q9H6Z9 1/20 0.44
ALDH1A1 P00352 2/20 0.43
PPARA Q07869 2/20 0.39
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
CNR2 P34972 6/20 0.37
CNR1 P21554 4/20 0.37
ALOX15 P16050 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HCAR2 Q8TDS4 1/20 0.36
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35
GABRG2 P18507 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL329962 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL330199 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL330677 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL10947939 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL7815097 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL17225894 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL330198 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL10795468 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL10947943 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1
SCHEMBL7815100 1.00 TSHR (0.44) TSHRTP53EGLN1EGLN3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419394-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.p.A. (IT) 2012-02-22 EP claimed
US-20120022282-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2012-01-26 US claimed
WO-2010119117-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2010-10-21 WO claimed
EP-2241543-A1 Process for the preparation of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol Giuliani S.p.A. (IT) 2010-10-20 EP claimed
EP-3041459-B1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI SPA (IT) 2019-04-03 EP disclosed
US-20160213635-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2016-07-28 US disclosed
EP-3041459-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER Giuliani S.p.A. (IT) 2016-07-13 EP disclosed
WO-2015033276-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2015-03-12 WO disclosed
EP-2419394-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.p.A. (IT) 2012-02-22 EP disclosed
EP-2419394-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.p.A. (IT) 2012-02-22 EP disclosed
US-20120022282-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2012-01-26 US disclosed
US-20120022282-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2012-01-26 US disclosed
WO-2010119117-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2010-10-21 WO disclosed
WO-2010119117-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL GIULIANI S.P.A. (IT) 2010-10-21 WO disclosed
EP-2241543-A1 Process for the preparation of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol Giuliani S.p.A. (IT) 2010-10-20 EP disclosed
EP-2241543-A1 Process for the preparation of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol Giuliani S.p.A. (IT) 2010-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022282-A1 PROCESS FOR THE PREPARATION OF 2,4,6-OCTATRIENE-1-OIC ACID AND 2,4,6-OCTATRIENE-1-OL OSTC, APEH, OXER1 TSHR 875/4885TP53 4545/4885EGLN1 1781/4885
US-20160213635-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER PKLR, AKR1C3, HK1 TSHR 3804/4885TP53 111/4885EGLN1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.